Summary The SCC-25 cell line is a well-established line derived from a human squamous carcinoma of the head and neck. The capacity of this cell line for recovery from potentially lethal damage following X-ray treatment has been documented. The survival curve of stationary phase SCC-25 cells exposed to various concentrations of bleomycin is biphasic with an initial sensitive phase and a less sensitive second phase as is common for many cell lines. Stationary phase SCC-25 cells were exposed to lOOmUml-1 of bleomycin for I h. The drug was removed and the cells were allowed various periods to recover from potentially lethal damage. After 24h, the SCC-25 cells showed a recovery ratio (RIRO) of 7.0 which corresponded to an immediate survival at a drug level of 27mUml-1, a dose 3.7-fold less than the exposure concentration of 100mUml-. Over the course of the first 4h following bleomycin exposure, 0.5pM CDDP was a very effective inhibitor of potentially lethal damage repair, giving a R/Ro of 1
respectively. NIPt and Pt(terpy) were examined at both 10 pM and 25 pM for their ability to inhibit potentially lethal damage recovery after bleomycin treatment. After I h, NIPt gave a recovery ratio of 1.3-1.4, and after 2-4 h the recovery ratio was 1.7-2.6. Pt(terpy) gave recovery ratios of 1.3-1.6 after 1 h and 1.5-1.8 after 24 h.
The antibiotic complex bleomycin has been shown to exhibit clinical usefulness in the treatment of squamous cell cancer of the head and neck (SCCHN) . Clinical efficacy has been noted in both palliative treatment of advanced disease and when administered prior to irradiation and/or surgery. Given as a single agent in the treatment of recurrent disease, response rates ranged from 6% to 45% with a short duration of remission (Turrisi et al., 1978) . However, when administered concomitantly with radiation therapy, bleomycin did not increase either response rate or survival time when compared to radiation therapy alone. Severe mucosal reactions in the majority of patients required discontinuation of therapy (Shah et al., 1981) . The lack of haematopoietic and hepatic toxicities suggested that bleomycin could be used in combination with other drugs giving significant response rates in patients with previously treated SCCHN (Ervin et al., 1981) . Recently, multiple drug regimens which include bleomycin have been shown to exhibit activity when given preoperatively and/or prior to irradiation. In combination with CDDP and methotrexate or vincristine, response rates range from 58% to 90% (Boeheim & Spoendlin, 1984; Spaulding et al., 1982) . Despite these high response rates, a proportion of patients did not respond. Additionally, drug resistance, upon tumour recurrence, has arisen in all patients treated with chemotherapy alone.
The present paper reports in vitro characteristics of the effects of bleomycin on a well characterized, human squamous cell carcinoma cell line cultured from biopsies of head and neck malignancies. We employed cells growing at low density for the determination of bleomycin responsiveness in exponentially growing cells. However, such exponentially growing cells account for only a portion of the total cell population of in vivo malignancies. A medium renewal without subculture. These plateau-phase cultures contain a large fraction of non-cycling, but potentially clonogenic, cells (Hahn & Little, 1972) . In such cultures, enhancement of cell survival may be observed when cells are allowed to repair by delaying cell subculture after exposure to chemical agents or X-rays. Any increase of cell survival after such treatment is referred to as potentially lethal damage repair (PLDR) (Ray et al., 1973; Weichselbaum et al., 1982) . We have employed a human squamous cell carcinoma cell line (SCC-25) to study PLDR following bleomycin treatment. We also have examined the influence of cis-diamminedichloroplatinum(II) (CDDP) and several other platinum complexes on bleomycin-induced PLDR. The effect of these drugs on PLDR following bleomycin treatment is of particular interest, since combinations of bleomycin and CDDP have shown enhanced efficacy in the treatment of SCCHN (Glick et al., 1980; Hong et al., 1980; Wittes et al., 1979 
, and trans-di(2-nitroimidazole)dichloroplatinum(II) (NIPt)] were prepared in our laboratory as previously described (Teicher et al., 1985) . (Frei et al., 1985; Teicher et al., 1986) . This cell line has a plating efficiency of 10-30% and a doubling time of 48 h (Frei et al., 1985) . Recovery ratios (R/RO) were calculated by dividing the surviving fraction immediately after drug exposure (RO) into the surviving fraction of cells at each time post-treatment (R) corrected for the cytotoxicity of the inhibitor. A recovery ratio of 1.0 means no recovery or repair of damage and a ratio of greater than 1.0 means recovery from PLD (Barranco & Townsend, 1986) .
Results
The SCC-25 cell line is a well-established line derived from a human squamous carcinoma of the head and neck. The capacity of this cell line for PLDR following X-ray treatment has been documented with a 24h recovery ratio (R/RO) of 6.2 (Weichselbaum, 1984) . Figure I shows the survival curve for stationary phase SCC-25 cells exposed to various concentrations of bleomycin. The survival curve is biphasic with an initial sensitive phase and a less sensitive second phase as is common for many cell lines (Twentyman, 1984) . After stationary phase SCC-25 cells were exposed to 100 mU ml -of bleomycin for 1 h, the drug was removed and the cells were allowed various periods for PLD recovery.
After 24h, the SCC-25 cells showed a recovery ratio (R/RO) of 7.0 which corresponded to an immediate survival at a drug level of 27 mU ml -, a dose 3.7-fold less than the exposure concentration of 100mUml-1. The recovery ratio for SCC-25 cells following bleomycin treatment increased rapidly at early time points. It was 2.5 at 1 h, 4.1 at 2 h and 5.3 at 4 h. The rate of recovery slowed after 4 h so that the recovery ratio was 6.1 at 6 h and 7.0 at 24 h.
Over the course of the first 4h of PLD recovery, 0.5,UM CDDP was a very effective inhibitor of PLDR (Figure 2 ).
For the first hour, while R/Ro was 2.5 for bleomycin alone, with 0.5 gM CDDP the R/Ro was 1.1. Between 2 and 4 h the R/Ro was 1.6-1.8 with CDDP and 4.1-5.3 without CDDP.
However, at the 6h point the cell survival in the presence of CDDP increased, producing a recovery ratio of 3.9 with CDDP compared to 6.1 without CDDP. Plant (1O pM) and Plato (10,UM) produced PLD recovery inhibition patterns very similar to that of CDDP. After 1 h the recovery ratios in the presence of Plant and Plato were 1.1-1.3. Between 2 and 4 h, Plato gave recovery ratios of 1.8-2.3 and Plant gave recovery ratios of 1.6-1.9. By 6 h both Plato and Plant were less effective inhibitors than CDDP, producing recovery ratios of 5.3 and 4.4 respectively.
NIPt and Pt(terpy) were examined at both 10pgM and 25 pM for their ability to inhibit PLD recovery after bleomycin treatment (Figure 2 ). There was no significant difference between PLDR inhibitory effects by the different concentrations of these agents. After 1 h, NIPt gave a recovery ratio of 1.3-1.4, at 2-4 h the recovery ratio was 1.7-2.6 and at 6 h the recovery ratio was 3.6-3.8. Pt(terpy) gave recovery ratios of 1.3-1.6 after I h, 1.5-1.8 at 2-4h and 3.5-4.0 at 6 h. With NIPt and Pt(terpy), there was a continuous increase in the recovery ratios compared to the more stepwise increase in recovery ratios with CDDP, Plant and Plato. 
Discussion
The significance of PLDR has remained controversial (Twentyman, 1984; Weichselbaum et al., 1982; Weichselbaum et al., 1984) ; however, it seems reasonable that drug combinations which inhibit the ability of tumour cells to repair significant portions of drug-induced damage will lead to improved clinical treatment. The ability of mammalian cells to recover from bleomycin-induced damage has been well-documented both in vitro and in vivo (Barranco & Townsend, 1986) . The process can be inhibited with actinomycin D, ethanol and hyperthermia (Barranco, 1978; Twentyman, 1984) or under hypoxic conditions by misonidazole (Korbelik et al., 1985) . More recently it has been shown that some platinum complexes can inhibit the recovery of V79 cells from radiation-induced cell kill (O'Hara et al., 1986) . We have shown that CDDP and four other novel platinum complexes can inhibit to a moderate degree PLD recovery of stationary phase SCC-25 cells treated with bleomycin. Increased repair is one possible mechanism of resistance to chemotherapeutic agents (Teicher et al., 1986) . Drug combinations which can inhibit these repair processes and overcome resistance would be of great value in the clinic. The platinum complexes used in this study have been previously shown to potentiate the cytotoxicity of mitomycin C, especially in hypoxic cells (Teicher et al., 1986) . It is possible, therefore, to speculate on the possibility of a drug combination including euoxic and hypoxic selective drugs such as bleomycin/mitomycin C and at low doses a platinum complex which may inhibit potentially lethal damage recovery from bleomycin cytotoxicity and potentiate mitomycin C cytotoxicity. Our data suggest new avenues for therapeutic research in SCCHN. Since repair of SCC-25 cells after treatment with bleomycin begins 1-2h after treatment, fractionated doses or long term infusion of bleomycin as proposed by Umezawa (1982) or intermittent large dose treatment may be superior. Also, since the addition of relatively non-toxic doses of the platinum complexes to bleomycin resulted in a significant reduction of PLD repair, the addition of other chemotherapeutic drugs such as CDDP may further enhance the therapeutic efficacy of bleomycin treatment of tumours.
